Nisa Investment Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-18,730
| Closed | -$56.9K | – | 3087 |
|
|
2024
Q4 | $56.9K | Buy |
18,730
+241
| +1% | +$1.05K | ﹤0.01% | 1649 |
|
|
2024
Q3 | $96K | Sell |
18,489
-422
| -2% | -$2.1K | ﹤0.01% | 1458 |
|
|
2024
Q2 | $48.6K | Buy |
18,911
+18,077
| +2,168% | +$61.7K | ﹤0.01% | 1677 |
|
|
2024
Q1 | $4.1K | Buy |
834
+124
| +17% | +$734 | ﹤0.01% | 2138 |
|
|
2023
Q4 | $6.24K | Buy |
710
+15
| +2% | +$123 | ﹤0.01% | 2102 |
|
|
2023
Q3 | $7.97K | Sell |
695
-25
| -3% | -$481 | ﹤0.01% | 2221 |
|
|
2023
Q2 | $18.2K | Buy |
720
+60
| +9% | +$1.87K | ﹤0.01% | 2131 |
|
|
2023
Q1 | $21K | Buy |
660
+600
| +1,000% | +$18.7K | ﹤0.01% | 2003 |
|
|
2022
Q4 | $1K | Buy |
60
+8
| +15% | +$183 | ﹤0.01% | 2541 |
|
|
2022
Q3 | $1K | Buy |
+52
| New | +$1.05K | ﹤0.01% | 2543 |
|
|
2022
Q1 | – | Sell |
-750
| Closed | -$10K | – | 2415 |
|
|
2021
Q4 | $10K | Sell |
750
-2,300
| -75% | -$38.3K | ﹤0.01% | 2031 |
|
|
2021
Q3 | $85 | Hold |
3,050
| – | – | ﹤0.01% | 1775 |
|
|
2021
Q2 | $90 | Hold |
3,050
| – | – | ﹤0.01% | 1746 |
|
|
2021
Q1 | $85 | Buy |
3,050
+1,900
| +165% | +$52.6K | ﹤0.01% | 1817 |
|
|
2020
Q4 | $33K | Sell |
1,150
-1,150
| -50% | -$29.8K | ﹤0.01% | 2053 |
|
|
2020
Q3 | $58K | Buy |
2,300
+245
| +12% | +$6.42K | ﹤0.01% | 1746 |
|
|
2020
Q2 | $50K | Buy |
2,055
+307
| +18% | +$6.06K | ﹤0.01% | 1592 |
|
|
2020
Q1 | $26K | Hold |
1,748
| – | – | ﹤0.01% | 1667 |
|
|
2019
Q4 | $28K | Sell |
1,748
-17,522
| -91% | -$272K | ﹤0.01% | 1639 |
|
|
2019
Q3 | $251K | Buy |
+19,270
| New | +$236K | ﹤0.01% | 1266 |
|
Other funds holding RVNC
Nisa Investment Advisors's RVNC Position: Q1 2025 in Review
Nisa Investment Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 18,730 shares — an estimated $56.9K sold.
Nisa Investment Advisors first reported a position in RVNC in Q3 2019 and held it in 20 quarters. The position peaked at $251K in Q3 2019. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Nisa Investment Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Nisa Investment Advisors sold 18,730 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $56.9K.
- Nisa Investment Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2019 and held it in 20 quarters.
- Nisa Investment Advisors's Revance Therapeutics, Inc. position peaked at $251K in Q3 2019.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Nisa Investment Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.